Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.

Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope H, Yu M, Cao W, Oswald JT, Dinarvand M, Mahmoudi M, Langer R, Kantoff PW, Farokhzad OC, Zetter BR, Shi J.

Nat Biomed Eng. 2018 Dec;2(12):968. doi: 10.1038/s41551-018-0331-x.

PMID:
31015729
2.

Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.

Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope H, Yu M, Cao W, Oswald JT, Dinarvand M, Mahmoudi M, Langer R, Kantoff PW, Farokhzad OC, Zetter BR, Shi J.

Nat Biomed Eng. 2018 Nov;2(11):850-864. doi: 10.1038/s41551-018-0284-0. Epub 2018 Sep 17. Erratum in: Nat Biomed Eng. 2018 Dec;2(12):968.

3.

Developing a novel FRET assay, targeting the binding between Antizyme-AZIN.

Ghalali A, Rice JM, Kusztos A, Jernigan FE, Zetter BR, Rogers MS.

Sci Rep. 2019 Mar 15;9(1):4632. doi: 10.1038/s41598-019-40929-4.

4.

Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.

Cheong JE, Zaffagni M, Chung I, Xu Y, Wang Y, Jernigan FE, Zetter BR, Sun L.

Eur J Med Chem. 2018 Jan 20;144:372-385. doi: 10.1016/j.ejmech.2017.11.037. Epub 2017 Dec 14.

PMID:
29288939
5.

Prohibitin 1 regulates tumor cell apoptosis via the interaction with X-linked inhibitor of apoptosis protein.

Xu Y, Yang W, Shi J, Zetter BR.

J Mol Cell Biol. 2016 Jun;8(3):282-5. doi: 10.1093/jmcb/mjw018. Epub 2016 Mar 29. No abstract available.

6.

Biomaterials for mRNA delivery.

Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR, Shi J.

Biomater Sci. 2015 Dec;3(12):1519-33. doi: 10.1039/c5bm00198f. Epub 2015 Aug 17.

7.

The Contribution of Angiogenesis to the Process of Metastasis.

Bielenberg DR, Zetter BR.

Cancer J. 2015 Jul-Aug;21(4):267-73. doi: 10.1097/PPO.0000000000000138. Review.

8.

Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment.

Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7779-84. doi: 10.1073/pnas.1505629112. Epub 2015 Jun 8.

9.

Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.

Banyard J, Chung I, Migliozzi M, Phan DT, Wilson AM, Zetter BR, Bielenberg DR.

BMC Cancer. 2014 May 30;14:387. doi: 10.1186/1471-2407-14-387.

10.

Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing.

Shi J, Xu Y, Xu X, Zhu X, Pridgen E, Wu J, Votruba AR, Swami A, Zetter BR, Farokhzad OC.

Nanomedicine. 2014 Jul;10(5):897-900. doi: 10.1016/j.nano.2014.03.006. Epub 2014 Mar 17.

11.

Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model.

Banyard J, Chung I, Wilson AM, Vetter G, Le Béchec A, Bielenberg DR, Zetter BR.

Sci Rep. 2013 Nov 6;3:3151. doi: 10.1038/srep03151.

12.

Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD, di Magliano MP.

Cancer Res. 2013 Oct 15;73(20):6359-74. doi: 10.1158/0008-5472.CAN-13-1558-T. Epub 2013 Oct 4.

13.

Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential.

Coughlin MF, Bielenberg DR, Lenormand G, Marinkovic M, Waghorne CG, Zetter BR, Fredberg JJ.

Clin Exp Metastasis. 2013 Mar;30(3):237-50. doi: 10.1007/s10585-012-9531-z. Epub 2012 Sep 8.

14.

Insulin-like growth factors promote vasculogenesis in embryonic stem cells.

Piecewicz SM, Pandey A, Roy B, Xiang SH, Zetter BR, Sengupta S.

PLoS One. 2012;7(2):e32191. doi: 10.1371/journal.pone.0032191. Epub 2012 Feb 21.

15.

A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis.

Spivey KA, Chung I, Banyard J, Adini I, Feldman HA, Zetter BR.

Oncogene. 2012 May 3;31(18):2362-72. doi: 10.1038/onc.2011.406. Epub 2011 Oct 3.

16.

Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo.

Olsen RR, Chung I, Zetter BR.

Amino Acids. 2012 Feb;42(2-3):549-58. doi: 10.1007/s00726-011-1032-x. Epub 2011 Sep 11.

17.

Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer.

Olsen RR, Zetter BR.

Mol Cancer Res. 2011 Oct;9(10):1285-93. doi: 10.1158/1541-7786.MCR-11-0178. Epub 2011 Aug 17. Review.

18.

miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo.

Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, Parissenti A, Duan Z, Voest EE, Zetter BR.

Oncogene. 2011 Oct 27;30(43):4386-98. doi: 10.1038/onc.2011.148. Epub 2011 May 9.

19.

Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling.

Freeman KW, Bowman BR, Zetter BR.

FASEB J. 2011 Mar;25(3):907-15. doi: 10.1096/fj.10-169417. Epub 2010 Nov 24.

PMID:
21106936
20.

Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.

Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR.

Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1362-72. doi: 10.1158/1055-9965.EPI-09-1095.

21.

Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR.

J Proteome Res. 2010 Jun 4;9(6):3073-82. doi: 10.1021/pr901211j.

22.

Self-assembled gold nanoparticle molecular probes for detecting proteolytic activity in vivo.

Mu CJ, Lavan DA, Langer RS, Zetter BR.

ACS Nano. 2010 Mar 23;4(3):1511-20. doi: 10.1021/nn9017334.

23.

Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells.

Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, Olsen RR, Waghorne C, Zetter BR.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2503-8. doi: 10.1073/pnas.0910649107. Epub 2010 Jan 25.

24.

Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1.

Banyard J, Barrows C, Zetter BR.

Genes Chromosomes Cancer. 2009 Jun;48(6):502-9. doi: 10.1002/gcc.20659.

25.

Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.

Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR.

Clin Cancer Res. 2009 Feb 1;15(3):1024-31. doi: 10.1158/1078-0432.CCR-08-1143.

26.

The scientific contributions of M. Judah Folkman to cancer research.

Zetter BR.

Nat Rev Cancer. 2008 Aug;8(8):647-54. doi: 10.1038/nrc2458. Epub 2008 Jul 17.

PMID:
18633354
27.

Meeting report: innovations in prostate cancer research.

Arap W, Trepel M, Zetter BR, Pasqualini R.

Cancer Res. 2008 Feb 1;68(3):635-8. doi: 10.1158/0008-5472.CAN-07-3232. Epub 2008 Feb 1. No abstract available.

28.

Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification.

Mangold U, Hayakawa H, Coughlin M, Münger K, Zetter BR.

Oncogene. 2008 Jan 24;27(5):604-13. Epub 2007 Jul 30.

PMID:
17667942
29.

Assessing enzyme activities using stable isotope labeling and mass spectrometry.

Everley PA, Gartner CA, Haas W, Saghatelian A, Elias JE, Cravatt BF, Zetter BR, Gygi SP.

Mol Cell Proteomics. 2007 Oct;6(10):1771-7. Epub 2007 Jul 11.

30.

Thymosin beta-NB is the human isoform of rat thymosin beta15.

Banyard J, Hutchinson LM, Zetter BR.

Ann N Y Acad Sci. 2007 Sep;1112:286-96. Epub 2007 Jun 13. Review.

PMID:
17567946
31.

Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.

Banyard J, Bao L, Hofer MD, Zurakowski D, Spivey KA, Feldman AS, Hutchinson LM, Kuefer R, Rubin MA, Zetter BR.

Clin Cancer Res. 2007 May 1;13(9):2634-42.

32.

Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.

Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR.

J Cell Sci. 2006 Jun 15;119(Pt 12):2583-91. Epub 2006 May 30.

33.

Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation.

Everley PA, Bakalarski CE, Elias JE, Waghorne CG, Beausoleil SA, Gerber SA, Faherty BK, Zetter BR, Gygi SP.

J Proteome Res. 2006 May;5(5):1224-31.

PMID:
16674112
34.

Ubiquitin-independent degradation and its implication in cancer.

Zetter BR, Mangold U.

Future Oncol. 2005 Oct;1(5):567-70. Review. No abstract available.

35.

Cancer biomarkers: knowing the present and predicting the future.

Chatterjee SK, Zetter BR.

Future Oncol. 2005 Feb;1(1):37-50. Review.

PMID:
16555974
36.

Proteomics in tumor progression and metastasis.

Everley PA, Zetter BR.

Ann N Y Acad Sci. 2005 Nov;1059:1-10. Review.

PMID:
16382037
37.

Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer.

Hutchinson LM, Chang EL, Becker CM, Ushiyama N, Behonick D, Shih MC, DeWolf WC, Gaston SM, Zetter BR.

Clin Biochem. 2005 Jun;38(6):558-71.

PMID:
15885237
38.

Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins.

Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR.

J Cell Biol. 2005 Feb 14;168(4):643-53. Erratum in: J Cell Biol. 2005 May 9;169(3):541.

39.

Use of thymosin beta15 as a urinary biomarker in human prostate cancer.

Hutchinson LM, Chang EL, Becker CM, Shih MC, Brice M, DeWolf WC, Gaston SM, Zetter BR.

Prostate. 2005 Jul 1;64(2):116-27.

PMID:
15666387
40.

Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells.

Cheng GC, Schulze PC, Lee RT, Sylvan J, Zetter BR, Huang H.

Exp Cell Res. 2004 Nov 1;300(2):297-307.

PMID:
15474995
41.

Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression.

Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR.

J Biol Chem. 2004 Oct 1;279(40):41504-11. Epub 2004 Jul 23.

42.

Identification of a transcriptional profile associated with in vitro invasion in non-small cell lung cancer cell lines.

Lader AS, Ramoni MF, Zetter BR, Kohane IS, Kwiatkowski DJ.

Cancer Biol Ther. 2004 Jul;3(7):624-31. Epub 2004 Jul 9.

PMID:
15153803
43.

Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research.

Everley PA, Krijgsveld J, Zetter BR, Gygi SP.

Mol Cell Proteomics. 2004 Jul;3(7):729-35. Epub 2004 Apr 21.

44.

Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells.

Banyard J, Bao L, Zetter BR.

J Biol Chem. 2003 Jun 6;278(23):20989-94. Epub 2003 Mar 18.

45.

Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1.

Becker CM, Farnebo FA, Iordanescu I, Behonick DJ, Shih MC, Dunning P, Christofferson R, Mulligan RC, Taylor GA, Kuo CJ, Zetter BR.

Cancer Biol Ther. 2002 Sep-Oct;1(5):548-53.

PMID:
12496487
46.

Cancer. The silence of the genes.

Zetter BR, Banyard J.

Nature. 2002 Oct 10;419(6907):572-3. No abstract available.

PMID:
12374961
47.

DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism.

Furman C, Short SM, Subramanian RR, Zetter BR, Roberts TM.

J Biol Chem. 2002 Mar 8;277(10):7962-9. Epub 2001 Dec 31.

48.

Hold that line. Angiomotin regulates endothelial cell motility.

Zetter BR.

J Cell Biol. 2001 Mar 19;152(6):F35-6. No abstract available.

49.

Molecular cloning and structural characterization of the rat thymosin beta15 gene.

Bao L, Zetter BR.

Gene. 2000 Dec 30;260(1-2):37-44.

PMID:
11137289
50.

C-terminal variations in beta-thymosin family members specify functional differences in actin-binding properties.

Eadie JS, Kim SW, Allen PG, Hutchinson LM, Kantor JD, Zetter BR.

J Cell Biochem. 2000 Mar;77(2):277-87.

PMID:
10723093

Supplemental Content

Loading ...
Support Center